Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Thorax 2007;62:1034-1036; doi:10.1136/thx.2007.079061
Copyright © 2007 BMJ Publishing Group Ltd & British Thoracic Society

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gibson, P. G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gibson, P. G
Topic Collections
Right arrowRelated Article

EDITORIALS

Non-eosinophilic asthma

What do non-eosinophilic asthma and airway remodelling tell us about persistent asthma?

Peter G Gibson

Correspondence to:
Professor Peter G Gibson, Level 3, Hunter Medical Research Institute, John Hunter Hospital, Locked Bag 1, Hunter Region Mail Centre, NSW 2310 Australia; peter.gibson@hnehealth.nsw.gov.au


There is still much more to learn about the pathogenesis and treatment of asthma

The first 150 words of the full text of this article appear below.

Over a decade of careful clinicopathological investigation has characterised the allergen-triggered Th2 response in asthma that leads to eosinophilic airway inflammation. This research has directed drug discovery programmes and we now have effective treatment for most steps in the eosinophilic asthma pathway. This list includes interventions that act at discrete levels such as allergen avoidance, allergen immunotherapy, anti-IgE antibodies, anti-interleukin-5 monoclonal antibodies and leucotriene receptor antagonists, together with corticosteroids that act on multiple levels in the pathway. Despite this significant success in therapeutic discovery, asthma persists. There must be something more to the pathogenesis of asthma. What could it be?

Airway remodelling and non-eosinophilic asthma (NEA) are both topical answers to this question. To date these have been pursued as distinct entities, but the paper by Berry and colleagues1 published in this issue of Thorax (see p 1043) addresses both issues and allows consideration of the . . . [Full text of this article]


Related Article

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma
Mike Berry, Angela Morgan, Dominick E Shaw, Deborah Parker, Ruth Green, Christopher Brightling, Peter Bradding, Andrew J Wardlaw, and Ian D Pavord
Thorax 2007 62: 1043-1049. [Abstract] [Full Text] [PDF]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & British Thoracic Society